Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy.
Saved in:
| Title: | Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. |
|---|---|
| Authors: | Little JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Medina Pena A; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Kim EB; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Yee AJ; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Midha S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Raje N; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Frigault MJ; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Cirstea DD; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Hammond SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA. |
| Source: | Blood advances [Blood Adv] 2025 Aug 26; Vol. 9 (16), pp. 4190-4194. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40561525 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Little+JS%22">Little JS</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Medina+Pena+A%22">Medina Pena A</searchLink>; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Kim+EB%22">Kim EB</searchLink>; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Yee+AJ%22">Yee AJ</searchLink>; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Nadeem+O%22">Nadeem O</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Midha+S%22">Midha S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Sperling+AS%22">Sperling AS</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Munshi+NC%22">Munshi NC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Raje+N%22">Raje N</searchLink>; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Frigault+MJ%22">Frigault MJ</searchLink>; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cirstea+DD%22">Cirstea DD</searchLink>; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Hammond+SP%22">Hammond SP</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Cellular Immunotherapy, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Aug 26; Vol. 9 (16), pp. 4190-4194. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE; In Process |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40561525 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1182/bloodadvances.2025016748 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 4190 Titles: – TitleFull: Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Little JS – PersonEntity: Name: NameFull: Medina Pena A – PersonEntity: Name: NameFull: Kim EB – PersonEntity: Name: NameFull: Yee AJ – PersonEntity: Name: NameFull: Nadeem O – PersonEntity: Name: NameFull: Midha S – PersonEntity: Name: NameFull: Sperling AS – PersonEntity: Name: NameFull: Munshi NC – PersonEntity: Name: NameFull: Raje N – PersonEntity: Name: NameFull: Frigault MJ – PersonEntity: Name: NameFull: Cirstea DD – PersonEntity: Name: NameFull: Hammond SP IsPartOfRelationships: – BibEntity: Dates: – D: 26 M: 08 Text: 2025 Aug 26 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2473-9537 Numbering: – Type: volume Value: 9 – Type: issue Value: 16 Titles: – TitleFull: Blood advances Type: main |
| ResultId | 1 |